An integrated analysis on the genomic, transcriptomic, proteomic, and clinical data from cohorts of lung adenocarcinoma patients revealed that TP53-mutated tumors showed prominently increased mutation burden [30]. The gene discussed is TP53; the disease is lung adenocarcinoma.